Dechra has announced the return of Canaural, a treatment for otitis externa, to the veterinary market.

Canaural contains fusidic acid, framycetin and nystatin for their antibacterial and antifungal effects against the most common organisms associated with otitis externa. 

Fusidic acid has skin penetrating properties and is active against staphylococci and streptococci¹. Framycetin is active against Gram negative species. Dechra says the combination of the two provides an enhanced antibacterial effect on the most common bacterial cause of canine otitis².  

Nystatin is active against malassezia and prednisolone helps to provide anti-inflammatory and anti-pruritic action.

Dechra Brand Manager Carol Morgan said: “The reintroduction of Canaural to the veterinary treatment market means that once again veterinarians have this reliable and effective treatment available to tackle one of the most common canine complaints. 

"Canaural is a tried and tested product and a recent study showed that fusidic acid is highly efficacious against both methicillin sensitive and methicillin resistant strains of Staphylococcus pseudintermedius³. Canaural remains as relevant today as it has ever been."

Canaural comes in 15 ml and 25 ml bottle sizes and is now available in veterinary wholesalers.  

References

1. Trial report GB 182 (2001)
2. Nuttall, T.J. et al (2011) Fusidic acid and framycetin show synergistic antimicrobial activity in vitro , Abstracts of the 25th Annual Congress of the ECVD-ESVD, 8–10 September 2011, Brussels, Belgium  Veterinary Dermatology, 22, 468 
3. Clark et al (2015) Susceptibility in vitro of canine methicillin-resistant and –susceptible staphylococcal isolates to fusidic acid, chlorhexidine and miconazole: opportunities for topical therapy of canine superficial pyoderma. Journal of Antimicrobial Chemotherapy 70 (7), 2048-2052  

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.